Effectiveness of COVID-19 vaccine BNT162b2 at age 12-15 years with one dose‏

Nadav Davidovitch, Oren Miron, Rachel Wilf-Miron

Research output: Working paperPreprint

Abstract

The clinical trial of BNT162b2 at age 12-15 years reported 100% effectiveness in preventing COVID-19 after 7 days from dose-2, which is administrated at day 21. We reanalyzed the data and found 100% effectiveness also after 14-20 days from dose-1 administration. This could relate to studies showing increased dose-1 effectiveness at younger ages. Our findings support the possibility of vaccinating younger ages with the United Kingdom regimen, which delays dose-2 to day 84 to allow more dose-1 vaccinations.
Original languageEnglish
DOIs
StatePublished - 2021

Fingerprint

Dive into the research topics of 'Effectiveness of COVID-19 vaccine BNT162b2 at age 12-15 years with one dose‏'. Together they form a unique fingerprint.

Cite this